Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. Hoboken: John Wiley & Sons; 2003.
Herson J. Data and safety monitoring committees in clinical trials. Boca Raton: Chapman & Hall/CRC/Taylor & Francis; 2009.
Anand SS, Wittes J, Yusuf S. What information should a sponsor of a randomized trial receive during its conduct? Clin Trials. 2011;8:716–9.
Friedman LM, Furberg C, DeMets DL. Fundamentals of clinical trials. 3rd ed. New York: Springer; 1998.
Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005;9:1–238. iii–iv.
Borer JS, Gordon DJ, Geller NL. When should data and safety monitoring committees share interim results in cardiovascular trials? JAMA. 2008;299:1710–2.
Bloudoff-Indelicato M. Threat of interim data leaks prompts call for international rules. Nat Med. 2015;21:200.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/home.html. Accessed Dec 2015.
Who we are. 2017. http://www.who.int/about/who-we-are/en/. Accessed Dec 2015.
Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R. RAMESES publication standards: meta-narrative reviews. BMC Med. 2013;11(1):20.
George SL. A survey of monitoring practices in cancer clinical trials. Stat Med. 1993;12(5-6):435–50.
Geller NL, Stylianou M. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH. Stat Med. 1993;12(5-6):543–51. discussion 553.
Tereskerz PM, Guterbock TM, Kermer DA, Moreno JD. An opinion and practice survey on the structure and management of data and safety monitoring boards. Account Res. 2011;18:1–30.
Silverman H. Ethical issues during the conduct of clinical trials. Proc Am Thorac Soc. 2007;4:180–4. discussion 184.
Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med. 2004;350(11):1143–7.
Fleming TR, Sharples K, McCall J, Moore A, Rodgers A, Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials. 2008;5:157–67.
Rouse DJ. Data monitoring and safety committees and their operations. Obstet Gynecol Surv. 2003;58(5):329–36.
Migrino RQ, Topol EJ. A matter of life and death? The Heart Protection Study and protection of clinical trial participants. Control Clin Trials. 2003;24(5):501–5.
Hemmings R, Day S. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data. Drug Saf. 2004;27:1–6.
US Food and Drug Administration. The establishment and operation of clinical trial data monitoring committees for clinical trial sponsors. Rockville: US Food and Drug Administration; 2006. p. 38.
Eckstein L. Building a more connected DSMB: better integrating ethics review and safety monitoring. Account Res Policies Qual Assur. 2015;22(2):81–105.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised tripartite guideline; statistical principles for clinical trials E9. Geneva: ICH; 1998. p. 39.
Chalmers I, Altman DG, McHaffie H, Owens N, Cooke RW. Data sharing among data monitoring committees and responsibilities to patients and science. Trials. 2013;14:102.
Shah SK, Dawson L, Dixon DO, Lie RK. Should sponsors and DSMBs share interim results across trials? J Acquir Immune Defic Syndr. 2011;58(5):433–5.
US Food and Drug Administration. FDA guidance on clinical trial data monitoring committees (DMCs). Rockville: US Food and Drug Administration; 2001. p. 237.
Pocock SJ. Statistical and ethical issues in monitoring clinical trials. Stat Med. 1993;12(15-16):1459–69. discussion 1471–5.
Chow SC, Corey R, Lin M. On the independence of data monitoring committee in adaptive design clinical trials. J Biopharm Stat. 2012;22(4):853–67.
Fleming TR, Hennekens CH, Pfeffer MA, DeMets DL. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. J Biopharm Stat. 2014;24(5):968–75.
D’Agostino Sr RB. The statistician and the data monitoring committee. Stat Med. 2004;23(10):1501–2.
Fleming TR. Standard versus adaptive monitoring procedures: a commentary. Stat Med. 2006;25(19):3305–12. discussion 3313–4, 3326–47.
Siegel JP, O’Neill RT, Temple R, Campbell G, Foulkes MA. Independence of the statistician who analyses unblinded data. Stat Med. 2004;23(10):1527–9.
NHLBI policy for data and safety monitoring of extramural clinical studies. http://www.nhlbi.nih.gov/research/funding/human-subjects/data-safety-monitoring-policy. Accessed Dec 2015.
Guidelines for NCCIH-appointed data and safety monitoring boards. https://nccih.nih.gov/research/policies/datasafety. Accessed Dec 2015.
Sartor O, Halabi S. Independent data monitoring committees: an update and overview. Urol Oncol. 2015;33(3):143–8.
Williams GW, Davis RL, Getson AJ, Gould AL, Hwang IK, Matthews H, Shih WCJ, Snapinn SM, Waltonbowen KL. Monitoring of clinical trials and interim analyses from a drug sponsors point of view. Stat Med. 1993;12(5-6):481–92.
DeMets D, Califf R, Dixon D, Ellenberg S, Fleming T, Held P, Julian D, Kaplan R, Levine R, Neaton J, et al. Issues in regulatory guidelines for data monitoring committees. Clin Trials. 2004;1(2):162–9.
Delgado-Herrera L, Anbar D. A model for the interim analysis process: a case study. Control Clin Trials. 2003;24:51–65.
DeMets DL, Fleming TR. The independent statistician for data monitoring committees. Stat Med. 2004;23(10):1513–7.
Stephens RJ, Langley RE, Mulvenna P, Nankivell M, Vail A, Parmar MK. Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential? Lung Cancer. 2014;85(2):116–8.
Green S, Crowley J. Data monitoring committees for Southwest Oncology Group clinical trials. Stat Med. 1993;12(5-6):451–5.
Lilford RJ, Braunholtz D, Edwards S, Stevens A. Monitoring clinical trials - interim data should be publicly available. Br Med J. 2001;323(7310):441–2.
Miller FG, Wendler D. Is it ethical to keep interim findings of randomised controlled trials confidential? J Med Ethics. 2008;34:198–201.
Vail A, Hornbuckle J, Spiegelhalter DJ, Thornton JG. Prospective application of Bayesian monitoring and analysis in an ‘open’ randomized clinical trial. Stat Med. 2001;20(24):3777–87.
Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Stat Med. 2002;21(19):2843–51.
Glover JM, Kay R. Who advises the Data Monitoring Committee (DMC)? A review of regulatory guidance for sponsors on DMCs after 5 years and advice for DMC members. Drug Inf J. 2012;46(5):525–31.
Califf RM, Ellenberg SS. Statistical approaches and policies for the operations of Data and Safety Monitoring Committees. Am Heart J. 2001;141(2):301–5.
Hicks LK, Laupacis A, Slutsky AS. A primer on data safety monitoring boards: mission, methods, and controversies. Intensive Care Med. 2007;33(10):1815–8.
DeMets DL. Relationships between Data Monitoring Committees. Control Clin Trials. 2000;21(1):54–5.
Dixon DO, Lagakos SW. Should data and safety monitoring boards share confidential interim data? Control Clin Trials. 2000;21:1–6. discussion 54–55.
Dixon DO, Weiss S, Cahill K, Fox L, Love J, McNamara J, Soto-Torres LE. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials. Clin Trials. 2011;8:727–35.
Yusuf, Whitley R, Assenzo R, Fleming T, Deykin, Hawkins B, Meier, Gent, Tognoni, Ellenberg J, et al. The operation of data monitoring committees - discussion. Stat Med. 1993;12(5-6):527–42.
Ellenberg SS. Independent data monitoring committees: rationale, operations and controversies. Stat Med. 2001;20:2573–83.
Wittes J, Barrett-Connor E, Braunwald E, Chesney M, Cohen HJ, Demets D, Dunn L, Dwyer J, Heaney RP, Vogel V, et al. Monitoring the randomized trials of the Women’s Health Initiative: the experience of the Data and Safety Monitoring Board. Clin Trials. 2007;4:218–34.
Peppercorn J, Buss WG, Fost N, Godley PA. The dilemma of data-safety monitoring: provision of significant new data to research participants. Lancet. 2008;371(9611):527–9.
Fleming TR. Protecting the confidentiality of interim data: addressing current challenges. Clin Trials. 2015;12(1):5–11.
Nissen SE. Commentary: confidentiality of interim trial data—the emerging crisis. Clin Trials. 2015;12(1):15–7.
US Food and Drug Administration, Department of Health and Human Services, Parks M, Rosebraugh C, Jenkins J, Woodcock J. Memorandum; disclosure of interim cardiovascular risk study data NDA 22271 Nesina (alogliptin) tablets and its fixed dose combination product NDAs 22426 and 203414. Rockville: US Food and Drug Administration; 2013.
US Food and Drug Administration. Presentations for: Part 15 public hearing; confidentiality of interim results in cardiovascular (CV) outcomes safety trials. Rockville: US Food and Drug Administration; 2014.
London AJ. Commentary: data monitoring confidentiality and FDA transparency. Clin Trials. 2015;12(1):12–4.
US Food and Drug Administration. Transcript for hearing: Part 15 public hearing; confidentiality of interim results in cardiovascular (CV) outcomes safety trials. Rockville: US Food and Drug Administration; 2014.
Confidentiality of Interim Results in Cardiovascular (CV) Outcomes Safety Trials; Part 15 - PUBLIC HEARING BEFORE THE COMMISSIONER; Request for Comments. http://www.fda.gov/Drugs/NewsEvents/ucm405023.htm. Accessed Dec 2015.
Gallo P. Operational challenges in adaptive design implementation. Pharm Stat. 2006;5(2):119–24.
Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development—an Executive Summary of the PhRMA Working Group. J Biopharm Stat. 2006;16(3):275–83. discussion 285–91, 293–8, 311–2.
Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Inf J. 2006;40(4):445–50.
Herson J. Coordinating data monitoring committees and adaptive clinical trial designs. Drug Inf J. 2008;42(4):297–301.
Antonijevic Z, Gallo P, Chuang-Stein C, Dragalin V, Loewy J, Menon S, Miller ER, Morgan CC, Sanchez M. Views on emerging issues pertaining to data monitoring committees for adaptive trials. Ther Innov Regul Sci. 2013;47(4):495–502.
Day S. Data monitoring committees in clinical trials: best practice, complexities and considerations. Clin Invest. 2015;5(7):615–7.
Gallo P, Fardipour P, Dragalin V, Krams M, Littman GS, Bretz F. Data monitoring in adaptive dose-ranging trials. Stat Biopharm Res. 2010;2(4):513–21.
Korn EL, Hunsberger S, Freidlin B, Smith MA, Abrams JS. Preliminary data release for randomized clinical trials of noninferiority: a new proposal. J Clin Oncol. 2005;23:5831–6.
Allardyce RA, Bagshaw PF, Frampton CM, Frizelle FA, Hewett PJ, Rieger NA, Smith JS, Solomon MJ, Stevenson AR. Ethical issues with the disclosure of surgical trial short-term data. ANZ J Surg. 2011;81(3):125–31.
DeMets DL. Commentary on Anand et al. Clin Trials. 2011;8:722–3. discussion 726.
Rockhold FW, Enas GG. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations. Stat Med. 1993;12(5-6):471–9.
DeMets DL, Fleming TR, Whitley RJ, Childress JF, Ellenberg SS, Foulkes M, Mayer KH, O’Fallon J, Pollard RB, Rahal JJ, et al. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. Control Clin Trials. 1995;16:408–21.
Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol. 1997;15(7):2736–43.